On Wednesday, Humana Inc. (NYSE: HUM) saw a shift in stock rating as Leerink Partners downgraded its view from Outperform to Market Perform. Along with the downgrade, the firm also revised its price target for Humana, lowering it to $250 from the previous target of $400.
The decision to downgrade Humana's stock was driven by various factors, including worries about the company's future performance. Leerink Partners pointed to challenges related to the Stars rating system that could impact Humana's performance in 2026. The firm expressed uncertainty about its previous recommendation and highlighted the difficulties in predicting a viable path to Humana's target margins.
Leerink Partners further detailed their concerns, emphasizing the rising trend and heightened industry risks that could affect the second half of the year's medical loss ratio (MLR) estimates. They also mentioned broader challenges within the Medicare Advantage (MA) sector.
Despite the downgrade for Humana, Leerink Partners remains optimistic about UnitedHealth (NYSE: UNH), maintaining an "Outperform" rating for the company. However, they did acknowledge potential minor challenges for UnitedHealth with the Stars rating system as well.
Recent news reveals a significant decrease in Humana's Medicare Advantage Star Ratings for 2025, with only around 25% of its members enrolled in plans rated 4 stars and above, a sharp decline from 94% in 2024. This decrease is largely attributed to Humana's contract H5216, which represents about 45% of its Medicare Advantage membership and dropped to a 3.5-star rating from 4.5 stars the previous year.
JPMorgan maintains a Neutral rating on Humana shares, recognizing the company's efforts to appeal the process with the Centers for Medicare & Medicaid Services (CMS) and implement cost-saving measures. Mizuho expressed concerns about the company's financial outlook, especially into fiscal year 2026, due to the lower star ratings.
Barclays suggested that a 10% reduction in bonus members could result in a $2.50 decrease in earnings per share (EPS). Despite these challenges, Humana reported strong growth in its Medicare business in the second quarter of 2024, raising its revenue guidance by $3 billion, primarily driven by membership growth. The company is actively working on initiatives to enhance operational discipline and improve member and provider engagement.
InvestingPro Insights
Recent data from InvestingPro sheds light on Humana's current position, providing context to Leerink Partners' downgrade. The company's stock has experienced a significant decline of 20.95% over the past month and a substantial 42.62% drop over the last year, aligning with concerns about its future performance.
Despite the challenges, Humana maintains a strong financial foundation with a market capitalization of $27.73 billion and revenue of $112.04 billion in the last twelve months, growing at a rate of 13.48%. The company's P/E ratio of 16.36 suggests that the stock may be undervalued based on its earnings.
InvestingPro Tips highlight that Humana has increased its dividend for 7 consecutive years and holds more cash than debt on its balance sheet, indicating financial stability. These factors may offer reassurance to investors amidst current uncertainties.
For a more in-depth analysis, InvestingPro provides 12 additional tips for Humana, offering a comprehensive view of the company's prospects in light of recent developments.
This article was generated with the support of AI and reviewed by an editor. For more information, see our T&C.
Analysis: Humana Inc. (NYSE: HUM) recently faced a downgrade in its stock rating by Leerink Partners, citing concerns about future performance. The company's challenges with the Stars rating system and the decline in Medicare Advantage Star Ratings have raised uncertainties among investors. Despite this, Humana maintains a strong financial foundation and has shown growth in its Medicare business. Investors should consider the potential impact of these factors on the company's stock performance and future outlook.